Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Lixte Biotechnology Holdings stock price, quote, forecast and news

LIXT
US5393193017
A3EGAA

Price

1.94
Today +/-
-0.01
Today %
-0.51 %
P

Lixte Biotechnology Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Lixte Biotechnology Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Lixte Biotechnology Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Lixte Biotechnology Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Lixte Biotechnology Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Lixte Biotechnology Holdings Stock Price History

DateLixte Biotechnology Holdings Price
9/9/20241.94 undefined
9/6/20241.95 undefined
9/5/20242.05 undefined
9/4/20241.92 undefined
9/3/20241.83 undefined
8/30/20241.78 undefined
8/29/20241.80 undefined
8/28/20241.65 undefined
8/27/20241.88 undefined
8/26/20242.00 undefined
8/23/20241.80 undefined
8/22/20241.80 undefined
8/21/20241.83 undefined
8/20/20242.02 undefined
8/19/20242.01 undefined
8/16/20242.00 undefined
8/15/20242.03 undefined
8/14/20242.08 undefined
8/13/20242.10 undefined
8/12/20242.12 undefined

Lixte Biotechnology Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Lixte Biotechnology Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Lixte Biotechnology Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Lixte Biotechnology Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Lixte Biotechnology Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Lixte Biotechnology Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Lixte Biotechnology Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Lixte Biotechnology Holdings’s growth potential.

Lixte Biotechnology Holdings Revenue, EBIT and net profit per share

DateLixte Biotechnology Holdings RevenueLixte Biotechnology Holdings EBITLixte Biotechnology Holdings Net Income
20230 undefined-5.09 M undefined-5.09 M undefined
20220 undefined-6.31 M undefined-6.31 M undefined
20210 undefined-6.72 M undefined-6.73 M undefined
20200 undefined-3.27 M undefined-3.26 M undefined
20190 undefined-2.49 M undefined-2.44 M undefined
20180 undefined-2.14 M undefined-2.13 M undefined
20170 undefined-1.81 M undefined-1.81 M undefined
20160 undefined-2.13 M undefined-2.13 M undefined
2015200,000 undefined-2.65 M undefined-2.85 M undefined
20140 undefined-2.4 M undefined-2.77 M undefined
20130 undefined-1.37 M undefined-1.37 M undefined
20120 undefined-2.11 M undefined-3.58 M undefined
20110 undefined-1.87 M undefined-2.07 M undefined
20100 undefined-880,000 undefined-880,000 undefined
20090 undefined-1.55 M undefined-1.55 M undefined
20080 undefined-1.27 M undefined-1.27 M undefined
20070 undefined-1.66 M undefined-1.65 M undefined
20060 undefined-450,000 undefined-560,000 undefined
20050 undefined-30,000 undefined-30,000 undefined

Lixte Biotechnology Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2005200620072008200920102011201220132014201520162017201820192020202120222023
0000000000000000000
-------------------
-------------------
0000000000000000000
00-1-1-10-1-2-1-2-2-2-1-2-2-3-6-6-5
-------------------
00-1-1-10-2-3-1-2-2-2-1-2-2-3-6-6-5
-------50.00-66.67100.00---50.00100.00-50.00100.00--16.67
0.050.380.450.470.490.580.590.650.690.740.780.80.930.981.121.131.351.581.92
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Lixte Biotechnology Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Lixte Biotechnology Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (k)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (k)TOTAL CAPITAL (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
                                     
00.680.510.011.571.720.371.660.480.260.130.21.314.272.65.074.825.354.2
000001200000000000000
0000000000000000000
0000000000000000000
070120404090709070280270230606060160270210105.14
00.750.630.051.611.930.441.750.550.540.40.431.374.332.665.235.095.564.31
0000000000000000000
0000000000000000000
0000000000000000000
0000000000000000000
0000000000000000000
0000000000000000000
0000000000000000000
00.750.630.051.611.930.441.750.550.540.40.431.374.332.665.235.095.564.31
                                     
00000000001.753.53.513.513.513.53.53.53.5
0.021.132.63.175.157.668.0713.0613.1815.9817.1317.422025.2726.0231.8638.3745.0648.98
-0.03-0.58-2.23-3.5-5.05-5.93-8-11.58-12.95-15.72-18.57-20.71-22.52-24.65-27.09-30.35-37.08-43.39-48.48
00001.200000000000000
0000000000000000000
-0.010.550.37-0.331.31.730.071.480.230.260.310.210.994.132.445.014.795.173.99
03070110803011080110120160160310200140190230230156.76
00000000000000010000
10170180170220170240180210150130606020902080170157.1
000100000000000000000
0000000000000000000
10200250380300200350260320270290220370220230220310400313.86
0000000000000000000
0000000000000000000
0000000000000000000
0000000000000000000
10200250380300200350260320270290220370220230220310400313.86
00.750.620.051.61.930.421.740.550.530.60.431.364.352.675.235.15.574.31
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Lixte Biotechnology Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Lixte Biotechnology Holdings's financial health and stability.

Assets

Lixte Biotechnology Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Lixte Biotechnology Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Lixte Biotechnology Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Lixte Biotechnology Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
00-1-1-10-2-3-1-2-2-2-1-2-2-3-6-6-5
0000000000000000000
0000000000000000000
0000000000000000000
0000000201000001210
0000000000000000000
0000000000000000000
000000-1-1-1-1-2-1-1-1-1-2-4-4-4
0000000000000000000
00000-1,0001,000000000000000
00000-1,0001,000000000000000
0000000000000000000
0000000000000000000
0100110201212404353
0100210201212404353
00001,00000000000000000
0000000000000000000
00001-101-100012-1200-1
-0.03-0.44-0.7-0.6-0.64-0.94-1.36-1.21-1.18-1.64-2.18-1.68-1.41-1.51-1.67-2.13-4.14-4.61-4.29
0000000000000000000

Lixte Biotechnology Holdings stock margins

The Lixte Biotechnology Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lixte Biotechnology Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lixte Biotechnology Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Lixte Biotechnology Holdings's sales revenue. A higher gross margin percentage indicates that the Lixte Biotechnology Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Lixte Biotechnology Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Lixte Biotechnology Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Lixte Biotechnology Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Lixte Biotechnology Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Lixte Biotechnology Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Lixte Biotechnology Holdings Margin History

Lixte Biotechnology Holdings Gross marginLixte Biotechnology Holdings Profit marginLixte Biotechnology Holdings EBIT marginLixte Biotechnology Holdings Profit margin
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %-1,325 %-1,425 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %

Lixte Biotechnology Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Lixte Biotechnology Holdings earnings per share therefore indicates how much revenue Lixte Biotechnology Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lixte Biotechnology Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lixte Biotechnology Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lixte Biotechnology Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lixte Biotechnology Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lixte Biotechnology Holdings Revenue, EBIT and net profit per share

DateLixte Biotechnology Holdings Sales per ShareLixte Biotechnology Holdings EBIT per shareLixte Biotechnology Holdings Earnings per Share
20230 undefined-2.66 undefined-2.66 undefined
20220 undefined-3.99 undefined-3.99 undefined
20210 undefined-4.98 undefined-4.99 undefined
20200 undefined-2.89 undefined-2.88 undefined
20190 undefined-2.22 undefined-2.18 undefined
20180 undefined-2.18 undefined-2.17 undefined
20170 undefined-1.95 undefined-1.95 undefined
20160 undefined-2.66 undefined-2.66 undefined
20150.26 undefined-3.4 undefined-3.65 undefined
20140 undefined-3.24 undefined-3.74 undefined
20130 undefined-1.99 undefined-1.99 undefined
20120 undefined-3.25 undefined-5.51 undefined
20110 undefined-3.17 undefined-3.51 undefined
20100 undefined-1.52 undefined-1.52 undefined
20090 undefined-3.16 undefined-3.16 undefined
20080 undefined-2.7 undefined-2.7 undefined
20070 undefined-3.69 undefined-3.67 undefined
20060 undefined-1.18 undefined-1.47 undefined
20050 undefined-0.6 undefined-0.6 undefined

Lixte Biotechnology Holdings business model

Lixte Biotechnology Holdings is one of the most popular companies on Eulerpool.com.

Lixte Biotechnology Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Lixte Biotechnology Holdings historical P/E ratio, EBIT, and P/S ratio.

Lixte Biotechnology Holdings shares outstanding

The number of shares was Lixte Biotechnology Holdings in 2023 — This indicates how many shares 1.916 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lixte Biotechnology Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lixte Biotechnology Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lixte Biotechnology Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lixte Biotechnology Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lixte Biotechnology Holdings Stock splits

In Lixte Biotechnology Holdings's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Lixte Biotechnology Holdings.

Lixte Biotechnology Holdings list of shareholders

%
Name
Stocks
Change
Date
6.84524 % Kovach (John S)154,01803/1/2024
5.92591 % John and Barbara Kovach 2015 Trust133,33303/1/2024
4.52591 % Arthur and Jane Riggs 1990 Irrevocable Trust101,83303/1/2024
4.41920 % Hightower Advisors, LLC99,43299,43212/31/2023
1.11111 % Bernards (Rene)25,00003/1/2024
0.62960 % Krinsky (Glenn L)14,16603/1/2024
0.48889 % Van Der Baan (Bastiaan Jeroen)11,00003/1/2024
0.35427 % Forman (Eric J)7,971-5,0003/1/2024
0.33244 % Forman (Stephen J.)7,48003/1/2024
0.31582 % Morgan Stanley Smith Barney LLC7,106012/31/2023
1
2
3
4

Lixte Biotechnology Holdings Executives and Management Board

Mr. Eric Forman43
Lixte Biotechnology Holdings Chief Operating Officer, Vice President
Compensation 244,459
Mr. Robert Weingarten71
Lixte Biotechnology Holdings Chief Financial Officer, Vice President
Compensation 240,640
Dr. James Miser76
Lixte Biotechnology Holdings Chief Medical Officer
Compensation 240,640
Mr. Bastiaan Van Der Baan51
Lixte Biotechnology Holdings Chairman of the Board, President, Chief Executive Officer (since 2022)
Compensation 170,394
Dr. Rene Bernards70
Lixte Biotechnology Holdings Independent Director
Compensation 133,873
1
2

Most common questions regarding Lixte Biotechnology Holdings

What is the P/E ratio of Lixte Biotechnology Holdings 2024?

The P/E ratio cannot be calculated for Lixte Biotechnology Holdings at the moment.

What is the P/S ratio of Lixte Biotechnology Holdings 2024?

The P/S cannot be calculated for Lixte Biotechnology Holdings currently.

What is the AlleAktien quality score of Lixte Biotechnology Holdings?

The AlleAktien quality score for Lixte Biotechnology Holdings is 4/10.

What is the revenue of Lixte Biotechnology Holdings 2024?

The revenue cannot currently be calculated for Lixte Biotechnology Holdings.

How high is the profit of Lixte Biotechnology Holdings 2024?

The profit cannot currently be calculated for Lixte Biotechnology Holdings.

What is the business model of Lixte Biotechnology Holdings

No history available for Lixte Biotechnology Holdings.

What is the Lixte Biotechnology Holdings dividend?

Lixte Biotechnology Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does Lixte Biotechnology Holdings pay dividends?

The dividend cannot currently be calculated for Lixte Biotechnology Holdings or the company does not pay out a dividend.

What is the Lixte Biotechnology Holdings ISIN?

The ISIN of Lixte Biotechnology Holdings is US5393193017.

What is the Lixte Biotechnology Holdings WKN?

The WKN of Lixte Biotechnology Holdings is A3EGAA.

What is the Lixte Biotechnology Holdings ticker?

The ticker of Lixte Biotechnology Holdings is LIXT.

How much dividend does Lixte Biotechnology Holdings pay?

Over the past 12 months, Lixte Biotechnology Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lixte Biotechnology Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Lixte Biotechnology Holdings?

The current dividend yield of Lixte Biotechnology Holdings is .

When does Lixte Biotechnology Holdings pay dividends?

Lixte Biotechnology Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lixte Biotechnology Holdings?

Lixte Biotechnology Holdings paid dividends every year for the past 0 years.

What is the dividend of Lixte Biotechnology Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lixte Biotechnology Holdings located?

Lixte Biotechnology Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lixte Biotechnology Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lixte Biotechnology Holdings from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Lixte Biotechnology Holdings pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Lixte Biotechnology Holdings in the year 2023?

In the year 2023, Lixte Biotechnology Holdings distributed 0 USD as dividends.

In which currency does Lixte Biotechnology Holdings pay out the dividend?

The dividends of Lixte Biotechnology Holdings are distributed in USD.

All fundamentals about Lixte Biotechnology Holdings

Our stock analysis for Lixte Biotechnology Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lixte Biotechnology Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.